2009's Private Biotech Acquisitions Are a Tale of Two Step-Ups

01 Jan 2010

• By Chris Morrison

Not every acquisition of a venture-backed biotech in 2009 was a structured deal that included earn-outs based on clinical or regulatory milestones. But it sure was close. Thirteen private biotechnology companies were acquired in 2009 and of those deals only a few did not include contingent value rights (CVRs).

Not every acquisition of a venture-backed biotech in 2009 was a structured deal that included earn-outs based on clinical or regulatory milestones. But it sure was close.

Thirteen private biotechnology companies were acquired in 2009 and of those deals only a few did not include contingent value...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Otsuka’s IgAN Data Top Some Vera Results, But To What End?

06 Jun 2025

• By Joseph Haas

Otsuka bested Vera on Phase III immunoglobulin A nephropathy data for proteinuria, but analysts wonder if the difference is especially meaningful.

Santen Sees Potential In Myopia Market After Ryjunea Approval

06 Jun 2025

• By Kevin Grogan

The low-dose atropine eye drop slowed the progression of pediatric myopia by 30%.

Europe’s Drugmakers Lament EU Pharma Package

05 Jun 2025

• By Kevin Grogan

EFPIA says reforms make the continent less attractive for innovative firms.

Bayer Boosted By Third FDA Approval For Nubeqa

04 Jun 2025

• By Kevin Grogan

US green light will further expand sales of the prostate cancer blockbuster.

A MoonLake Buyout Would Boost Merck & Co’s Immunology Ambitions

05 Jun 2025

• By Andrew McConaghie

As the patent protection clock ticks down on Merck’s flagship blockbuster Keytruda, the company is reported to be pursuing the inflammation and immunology biotech. Such a move would bulk up its sparse I&I pipeline.